The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., May. 26, 10:12 PM

Slide #5. OvaScience Secondary Offering

Company: OvaScience (NASDAQ:OVAS)
Date announced: 5/25/2016
Shares Offered: 7,150,000
Date of Pricing: 5/26/2016
Price Per Share: $7.00
Secondary Offering Details: OvaScience (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase additional shares of the common stock to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience. -updated 5/26- OvaScienceSM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has priced its previously announced underwritten public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share. Net proceeds to OvaScience from this offering are expected to be approximately $46.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENTSM treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrimeSM treatment and the OvaTureSM treatment, and working capital and other general corporate purposes. OvaScience has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock offered in the public offering. All of the shares in the offering will be sold by OvaScience. The offering is expected to close on June 1, 2016, subject to customary closing conditions. Leerink Partners LLC is acting as sole book runner for the offering. Oppenheimer & Co. Inc., H. C. Wainwright & Co., Roth Capital Partners, LLC and JonesTrading Institutional Services LLC are acting as co-managers for the offering.

OvaScience is a fertility company focused on the discovery, development, and commercialization of fertility treatments. Co.'s technology is based on Egg precursor (EggPCsm) cells, which are found in the protective outer layer of a woman's own ovaries. Co.'s portfolio of fertility treatment options uses its technology including methods to identify and isolate EggPC cells from a patient's own ovarian tissue. By applying its EggPC technology platform, Co. is developing and commercializing fertility treatment options that are designed to improve egg health and in vitro fertilization. Co.'s portfolio of fertility treatment options include: AUGMENTsm, OvaPrimesm, OvaTuresm, and OvaXonsm.

OVAS SEC Filing Email Alerts Service

Open the OVAS Page at The Online Investor »

Company Name:  OvaScience Inc.
Website:  www.ovascience.com
Sector:  Biotechnology
Number of ETFs Holding OVAS:  19
Total Market Value Held by ETFs:  $8.43M
Total Market Capitalization:  $250.00M
% of Market Cap. Held by ETFs:  3.37%
 

Open the OVAS Page at The Online Investor (in a new window) »

May 26, 2016    10:12 PM Eastern
Quotes delayed 20 minutes



Buy (2.67 out of 4)
26th percentile
(ranked lower than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.